Loading data for ABOS — first visit, this takes a few seconds.
Acumen Pharmaceuticals, Inc. (ABOS)
NasdaqGS: ABOS
· 实时价格 · USD
3.03
+0.11 (3.77%)
收盘价： Sep 02, 2026, 8:00 PM
股价、关键数字和最新消息，都在这一页。
Acumen Pharmaceuticals, Inc.（ABOS）股价、分析与数据
暂无数据
| 买价 | 2.08 |
| 市值 | 224M |
| 营收（TTM） | n/a |
| 净利润（TTM） | -105M |
| 0.33 | |
| -1.74 | |
| n/a | |
| -2.16 | |
| 市净率（TTM） | 3.91 |
| 市销率（TTM） | 0.00 |
| 财报日期 | Nov 11, 2026 |
| 卖价 | 3.81 |
| 成交量 | 126,249 |
| 20日均量 | 467,058 |
| 开盘价 | 2.93 |
| 前收盘价 | 2.92 |
| 日内区间 | 2.93 - 3.11 |
| 52周区间 | 1.21 - 3.60 |
| 分析师 | n/a |
| 目标价 | n/a |
| 分红 | n/a |
| 除息日 | n/a |
关于 ABOS
Acumen Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops targeted therapies for the treatment of Alzheimer's disease. It focuses on advancing a targeted immunotherapy drug candidate, sabirnetug (ACU193), which is in its Phase 2 ALTITUDE-AD clinical trial to target toxic soluble amyloid beta oligomers. Acumen Pharmaceuticals, Inc. has a collaboration and license agreement with Halozyme, Inc. for the development of a subcu...
公司完整简介财报意外
Acumen Pharmaceuticals 已于 Aug 12, 2026 发布季度财报：
- 营收为 $0 低于预期 $0, ， NaN% 同比增长.
- 每股收益为 -0.45 低于预期 -0.04, ， 33.82% 同比增长.
第 1 页，共 2 页